Imprimis’ Ophthalmic Sales Grow 105 Percent in Q1-2017

May 12, 2017: By Jon Swedien

Imprimis’ ophthalmology-related sales in Q1-2017 totaled $3.7 million, a 105 percent increase over Q1-2016, the San Diego-based company reported May 10.

The company’s total revenues for Q1-2017 were $6.1 million, a 39 percent increase compared with Q1-2016, said Imprimis, a pharmaceutical company focused on increasing patient access and affordability to critical medicines.

Imprimis said its total sales for March were the highest monthly revenues recorded in the company’s history and represented a significant increase over previous months.

CEO Mark Baum attributed some of the company’s recent success to its US FDA-registered outsourcing facility—which began shipping products in February—that allows customers to order products without specific prescription information, enabling them to have an inventory of Imprimis products on hand.

Baum said sales were also bolstered because Imprimis had five ophthalmic formulations come online in March.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Quidel Acquires RPS’ InflammaDry, AdenoPlus Ophthalmic Diagnostic Tests

Gottlieb Says US FDA Can Help Reduce Drug Prices through Generics, Biosimilars

ONL Therapeutics Closes $4.25 Million Series A Financing

Omeros’ Omidria Revenues Total $12.3 Million in Q1-2017

Finland Eye Care Provider Silmäasema Oyj Plans IPO to Raise €35 Million

Alcon Introduces SYSTANE ICAPS Chewable Eye Vitamin

Aerie’s Rhopressa Gets Target Action Date from US FDA

STAAR’s EVO+ Visian ICL with Aspheric (EDOF) Optic Receives CE Mark Approval

Refocus to File for US Approval of VisAbility for Presbyopia in Q3-2017

Trial for James Mazzo Ends in Hung Jury; Co-defendants DeCinces, Parker Convicted

Alcon Names Stephen S. Lane, MD, as Chief Medical Officer

Allergan’s Restasis Sales Increase 3.4 Percent in Q1-2017

Ophtec Secures CE Marking for Aspheric Presbyopia-Correcting IOL

LENSAR Becomes Subsidiary of PDL, Gains FDA Clearance for Laser Integration with Pentacam, Aladdin

Bausch + Lomb Posts Q1-2017 Revenues of $1.15 Billion in ‘Solid Quarter’

Carl Zeiss Meditec’s Revenues Grow 8.6 percent in First Half of Fiscal Year

Hoya’s Reports Strong IOL Sales in Fiscal 2017 Fourth Quarter

Shire Licenses Parion’s P-321 for Dry Eye Disease

Imprimis’ Ophthalmic Sales Grow 105 Percent in Q1-2017

Bernie Haffey Named Chief Commercial Officer at SightLife Surgical

Coming soon

2017 Ophthalmic Laser Report: A Global Market Analysis for 2016 to 2022 (Photocoagulation, Photodisruption, and SLT)